Table 8.
Types of nano-radiosensitizers mutiple drugs in combination with IR in NSCLC.
| Nanoparticles | Cells | Mechanism | Outcomes | Reference |
|---|---|---|---|---|
| Folate-coupled multifunctional dual drug loaded NPs encapsulating NU7441 and gemcitabine | A549, H460 | Endocytosis and release in acidic environment. | Increased apoptosis; enhanced radiosensitivity. | (76) |
| Ephrin-coupled NPs | A549 | Co-loaded with NU7441 and cisplatin; targeting NSCLC. | Significantly increased radiosensitivity. | (77) |
| Diblock Copolymer NPs | H460 | Sequential release of warfarin and docetaxel. | Superior therapeutic effect compared to other treatments. | (78) |
| C-siPLK1-NPs carrying Cetuximab and siPLK1 | A549, H460 | Reduced PLK1 expression; induced G2/M blockade. | Acted as radiosensitizer. | (79) |
| Fe3O4 magnetic nanoparticles loaded with SiBIRC5 and BIRC5 antisense sequence | A549, H460 | Reduced BIRC5 expression; increased death receptor 5 expression. | Improved radiotherapy efficacy. | (80) |
| NTSR1 ligand-coupled NPs loading DOX & 5-aminolevulinic acid | H1299 | Targeted cytotoxic effects; amplified radiation-induced stress. | Enhanced killing effect of radiation. | (81) |
| siXIAP Liposomes | H1299 | Transporting siXIAP into p53 wild-type/mutant cells. | Significantly enhanced radiosensitivity, especially in p53-mutant cells. | (82) |
| Lip-mS combining mS-T34A plasmid with liposomes | Lewis | Inhibit survivin. | Increased apoptosis, inhibited tumor angiogenesis, enhanced radiosensitivity. | (83) |
| Nano-lipid Polymers with KU55933 | H460 | Inhibit DNA repair. | Improved radiosensitizing effect. | (84) |
| Anti-CD40 Nanopolymers | Lewis | Encapsulated with anti-CD40 antibody for radio-immunotherapy. | Slowed tumor growth in and out of irradiated fields, improved survival. | (86) |
| TPP- Lonidamine@Lip | A549 | Activated AMPK, reduced PD-L1. | Enhanced anti-tumor immunity, increased radiosensitivity. | (87) |